Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21327096 | 0.92 | KDM4E (0.52) | MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL383618 | 0.89 | FOLH1 (0.58) | MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL21662749 | 0.89 | KDM4A (0.46) | MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL21662629 | 0.89 | KDM4E (0.50) | MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL384030 | 0.87 | MAOB (0.57) | MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL21327265 | 0.84 | ALDH1A1 (0.56) | MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4472145 | 0.84 | MRGPRX4 (0.49) | MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL21327204 | 0.84 | MCL1 (0.54) | MRGPRX4CYP2C9CYP2C19PTGER1MCL1 | |
| SCHEMBL644309 | 0.84 | ABCB1 (0.49) | MRGPRX4KDM4EALDH1A1PTGER1MCL1 | |
| SCHEMBL5460706 | 0.82 | PTGER1 (0.65) | MRGPRX4CYP2C9PTGER1KMT2AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751200-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-110114071-B | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-3534903-B1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2022-08-03 | — | — | EP | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3534903-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2370437-B1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-04 | — | — | EP | disclosed |
| US-8309578-B2 | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-13 | — | — | US | disclosed |
| US-20110294790-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-01 | — | — | US | disclosed |
| EP-2370437-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010060854-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294790-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | HSP90AB1, HSP90AA1, HSP90AB2P | MRGPRX4 3064/4885KDM4E 4098/4885ALDH1A1 1348/4885 |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | MRGPRX4 3248/4885KDM4E 326/4885ALDH1A1 2110/4885 |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | MRGPRX4 3248/4885KDM4E 326/4885ALDH1A1 2110/4885 |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | MRGPRX4 3248/4885KDM4E 326/4885ALDH1A1 2110/4885 |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | MRGPRX4 3248/4885KDM4E 326/4885ALDH1A1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.